Boston Scientific Corporation
$41.98-$1.01 (-2.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $72.6B
- P/E
- 25.1x
- EV / EBITDA
- 16.1x
- Revenue
- $20.1B
- Net margin
- 14.4%
- ROCE
- 10.4%
Price chart
Technical chartScreen technicals →-56.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -7.9%
- 3M
- -15.0%
- 6M
- -25.9%
- 1Y
- -56.5%
- 5Y
- +2.3%
52-week range
Day change -$1.01 (-2.3%) from $43 to $42 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BSX, bought on each weekday since 2021.
News & filings
What Boston Scientific filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthNet profit grew 60.7% a year over three years.
Concerns (1)
- The P/E of 25.1 is 44% above the peer median of 17.4.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Read moreShow less
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 1.48B
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $72.6B
- P/E
- 25.1x
- P/B
- 3.0x
- EV / EBITDA
- 16.1x
- EV / Sales
- 4.1x
- P/S
- 3.6x
- 52-week high
- $101.58
- 52-week low
- $41.58
Profitability
- Operating margin
- 19.8%
- Net margin
- 14.4%
- EBITDA margin
- 25.4%
- ROE
- 12.0%
- ROCE
- 10.4%
- ROA
- 6.6%
- Asset turnover
- 0.46
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $20.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 19.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 16.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 56.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $3.4B
Solvency
- Current ratio
- 1.62
- Debt / Equity
- 0.47
- Debt / Assets
- 0.26
- CFO / Net profit
- 1.56
- Cash / Market cap
- 2.7%
Where the revenue went
Of every $100 of FY2025 revenue, $14 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $6.2B |
| Revenue | Gross profit | $13.9B |
| Gross profit | Research and development | $2.1B |
| Gross profit | Selling, general and administrative | $6.9B |
| Gross profit | Other operating expenses | $943.0M |
| Gross profit | Operating income | $4.0B |
| Operating income | Pretax income | $3.4B |
| Operating income | Interest and other expense | $586.0M |
| Pretax income | Tax and other | $487.0M |
| Pretax income | Net income | $2.9B |
Revenue and net profit
Revenue grew 19.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $12.7B | $698.0M |
| FY2023 | $14.2B | $1.6B |
| FY2024 | $16.7B | $1.9B |
| FY2025 | $20.1B | $2.9B |
Cash flows
FY2025: $4.5B from operations, $3.4B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.5B | $914.0M |
| FY2023 | $2.5B | $1.7B |
| FY2024 | $3.4B | $2.4B |
| FY2025 | $4.5B | $3.4B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $20.1B+19.9%1Y
- EBITDA
- $5.1B+32.3%1Y
- Net profit
- $2.9B+56.3%1Y
- Cash from operations
- $4.5B+32.0%1Y
- Free cash flow
- $3.4B+43.9%1Y
- Revenue CAGR, 3Y
- 16.5%
- Net profit CAGR, 3Y
- 60.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $20.1B | $5.1B | $2.9B | $3.4B | 12.0% | +19.9% | +56.3% |
Monthly returns
Month-by-month returns of BSX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $43.7B |
| Current assets | $8.8B |
| Non-current assets | $34.9B |
| Liabilities | $19.2B |
| Current liabilities | $5.4B |
| Non-current liabilities | $13.8B |
| Equity | $24.5B |
| Paid-in capital | $21.5B |
| Retained earnings | $5.6B |
| Treasury stock | $2.3B |
| Minority interest | $239.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BSX highlighted.
P/E against peers
BSX trades at 25.1x earnings against a peer median of 17.4x (a 44% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Boston Scientific CorporationBSXthis companyP/E ↑ premium | $72.6B | 25.1x | 3.0x | 12.0% | 16.1x |
| McKesson CorporationMCK | $91.0B | 19.1x | -41.9x | -219.2% | 13.3x |
| Elevance Health, Inc.ELV | $88.9B | 15.7x | 2.0x | 12.9% | — |
| HCA Healthcare, Inc.HCA | $80.3B | 11.8x | -13.3x | -112.6% | 8.2x |
| The Cigna GroupCI | $74.2B | 12.5x | 1.8x | 14.3% | 10.2x |
| Regeneron Pharmaceuticals, Inc.REGN | $65.9B | 14.6x | 2.1x | 14.4% | 11.3x |
| Cencora, Inc.COR | $52.6B | 33.8x | 34.9x | 103.1% | 14.9x |
| Edwards Lifesciences CorporationEW | $50.4B | 46.9x | 4.9x | 10.4% | 33.2x |
| Cardinal Health, Inc.CAH | $47.2B | 30.3x | -17.0x | -56.1% | 16.7x |
| Peer median | — | 17.4x | 1.9x | 11.6% | 13.3x |
Year-to-date ROI
BSX since 1 January, against earlier years.
Historical volatility
BSX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 16.0% |
| FY2023 | 17.0% |
| FY2024 | 17.9% |
| FY2025 | 19.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $20.1B |
| Cost of revenueCost Of Revenue | $6.2B |
| Gross profitGross Profit | $13.9B |
| Operating expensesOperating Expense | $9.9B |
| Research and developmentResearch And Development | $2.1B |
| Selling, general and administrativeSelling General And Administration | $6.9B |
| Other operating expensesOther Operating Expenses | $46.0M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $897.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $897.0M |
| Amortization | $897.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $897.0M |
| Total expensesTotal Expenses | $16.1B |
| Operating incomeOperating Income | $4.0B |
| Interest and other | |
| Pretax incomePretax Income | $3.4B |
| TaxTax Provision | $493.0M |
| Net incomeNet Income | $2.9B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $43.7B |
| Current assetsCurrent Assets | $8.8B |
| Non-current assetsTotal Non Current Assets | $34.9B |
| LiabilitiesTotal Liabilities Net Minority Interest | $19.2B |
| Current liabilitiesCurrent Liabilities | $5.4B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $13.8B |
| EquityTotal Equity Gross Minority Interest | $24.5B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $4.5B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $4.5B |
| Net income, continuing operationsNet Income From Continuing Operations | $2.9B |
| Depreciation and amortisationDepreciation And Amortization | $1.4B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $1.4B |
| Depreciation | $471.0M |
| Amortization cash flowAmortization Cash Flow | $897.0M |
| Amortization of intangiblesAmortization Of Intangibles | $897.0M |
| Stock-based compensationStock Based Compensation | $299.0M |
| Deferred taxDeferred Tax | -$2.0M |
| Deferred income taxDeferred Income Tax | -$2.0M |
| Operating gains and lossesOperating Gains Losses | -$139.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$139.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | — |
| Asset impairmentAsset Impairment Charge | $170.0M |
| Change in working capitalChange In Working Capital | -$246.0M |
| Other non-cash itemsOther Non Cash Items | $192.0M |
| Investing cash flowInvesting Cash Flow | -$2.6B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$2.6B |
| Capital expenditureCapital Expenditure | -$1.1B |
| Purchase of PP&EPurchase Of PPE | -$876.0M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$876.0M |
| AcquisitionsPurchase Of Business | -$1.6B |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$1.6B |
| Purchase of investmentsPurchase Of Investment | — |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Purchase of intangiblesPurchase Of Intangibles | -$254.0M |
| Sale of intangiblesSale Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$254.0M |
| Other investing changesNet Other Investing Changes | $83.0M |
| Financing cash flowFinancing Cash Flow | -$395.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$395.0M |
| Debt issuedIssuance Of Debt | $1.6B |
| Debt repaidRepayment Of Debt | -$2.0B |
| Net debt issuedNet Issuance Payments Of Debt | -$491.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | -$1.8B |
| Net short-term debt issuedNet Short Term Debt Issuance | -$1.8B |
| Long-term debt issuedLong Term Debt Issuance | $1.6B |
| Long-term debt repaidLong Term Debt Payments | -$258.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $1.3B |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $151.0M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Dividends paidCash Dividends Paid | — |
| Preferred stock dividend paidPreferred Stock Dividend Paid | — |
| Other financing chargesNet Other Financing Charges | -$55.0M |
| Change in cashChanges In Cash | $1.5B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 4,200.0% |
| Cash at the start of the yearBeginning Cash Position | $606.0M |
| Cash at the end of the yearEnd Cash Position | $2.1B |
| Free cash flowFree Cash Flow | $3.4B |
| Supplemental |
Learn while you research
Academy chapters picked for Boston Scientific Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read